![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, March 01, 2010 10:39:19 AM
Press Release Source: Harbor BioSciences, Inc. On Monday March 1, 2010, 8:30 am EST
SAN DIEGO, March 1, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR - News) today announced it will present a poster at the ASCO Genitourinary Cancers Symposium in San Francisco this week, reporting additional results from a Phase I/IIa clinical trial of Apoptone(R) (HE3235), its anticancer drug candidate being developed for prostate cancer. Apoptone is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to induce cell death (apoptosis) in animal models of prostate and breast cancers.
Presenting the poster is the lead investigator of the study, R. Bruce Montgomery, M.D., Associate Professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine. The study is being conducted with participating member sites of the Prostate Cancer Clinical Trial Consortium (PCCTC).
Title: HE3235, a synthetic adrenal hormone, in castrate resistant prostate cancer (CRPC)
patients: Clinical Phase I/II trial results
Poster No.: 235
Presentation Time: Saturday, March 6, 12:30 p.m. to 2:00 p.m.
About Harbor BioSciences, Inc.
Harbor BioSciences is a development-stage company with two product candidates in clinical trials: Apoptone, in the cohort expansion portion of a Phase I/IIa trial of patients with late-stage prostate cancer, and Triolex(R), in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone and Triolex represent the lead candidates from Harbor BioSciences' small molecule platform based on metabolites or synthetic analogs of endogenous steroid hormones. For more information on Harbor BioSciences please visit www.harborbiosciences.com.
Recent HRBR News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/16/2024 09:51:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:35:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/15/2023 02:48:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 09:04:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:36:23 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM